Aeterna Zentaris: Poster on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130 (Macimorelin, Solorel) to be Presented at Upcoming 5th International Congress of the GRS-IGF Society in New York

President and CEO, Juergen Engel, Ph.D., to present corporate overview at upcoming BioContact in Quebec City

 

QUÉBEC CITY, Sept. 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130 (macimorelin, Solorel(TM)), will be presented at the upcoming 5th International Congress of the GRS-IGF Society, which will be held October 3 through 7, 2010 in New York City. AEZS-130 (macimorelin, Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.

 

    Poster Title:      "AEZS-30 (Macimorelin, Solorel (TM)) an Oral Ghrelin
                       Mimetic GH Secretagogue, as a Potential Diagnostic
                       Test for Adult GH Deficiency", Biller, Beverly M.K.,
                       M.D., K.C.J. Yuen, V. Bonert, M. Chen, A. Dobs,
                       J.M. Garcia, M. Kipnes, M. Molitch, R. Swerdloff,
                       C. Wang, D. Cook, I.R. Altemose, G.R. Merriam

    Presenter:         Beverly M.K. Biller, M.D, Harvard Medical
                       School/Massachusetts General Hospital, Boston, MA

    Date and Time:     Tuesday, October 5, 2010 from 1:00 p.m. to
                       2:00 p.m. (eastern)

    Poster Board #:    3

    Location:          Metropolitan Ballroom West, Sheraton New York Hotel,
                       New York

 

The Company also announced that its President and CEO, Juergen Engel, Ph.D., will present a corporate overview at BioContact Québec on Wednesday, October 6, 2010, at 9:30 a.m. (eastern) in the Frontenac Room of the Fairmont Château Frontenac in Quebec City, Canada.

 

About Aeterna Zentaris Inc.

 

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

CONTACT: Investor Relations: Ginette Vallieres, Investor Relations Coordinator, (418) 652-8525 ext. 265, gvallieres@aezsinc.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, pburroughs@aezsinc.com
 

Posted: September 2010

View comments

Hide
(web5)